Loading

Please wait...

Zinbryta

Generic Name: daclizumab (dah KLIH zyoo mab)
Brand Names: Zinbryta
  • Prescription Settings

Prices and coupons of Zinbryta

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Zinbryta (daclizumab) is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Zinbryta is used to treat relapsing forms of multiple sclerosis. Zinbryta is usually given when other medicines have not been effective. Zinbryta is available only from a certified pharmacy under a special program. You must be registered in the program and understand the risks and benefits of taking this medicine. Learn more

Zinbryta Side Effects

Zinbryta Side Effects

Note: This document contains side effect information about daclizumab. Some of the dosage forms listed on this page may not apply to the brand name Zinbryta.

In Summary

Common side effects of Zinbryta include: antibody development and hyperglycemia. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to daclizumab: parenteral injection

Warning

Special Alerts:

Notice: On March 2, 2018, Biogen and Abbvie announced a worldwide voluntary withdrawal of daclizumab (Zinbryta®) prompted by reports of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, associated with the drug; daclizumab will no longer be available in the US market after April 30, 2018.

Patients currently receiving daclizumab should not discontinue therapy without consulting their healthcare provider and should contact a clinician immediately if they experience any new or unexplained symptoms. Patients transitioning from daclizumab therapy should continue to undergo safety monitoring in accordance with the manufacturer's recommendations and the REMS program. (See REMS.)

For additional information concerning the withdrawal of daclizumab, contact the manufacturer at 866-633-4636 or at [Web].

REMS:

FDA approved a REMS for daclizumab to ensure that the benefits outweigh the risk. The REMS may apply to one or more preparations of daclizumab and consists of the following: communication plan, elements to assure safe use, and implementation system. See the FDA REMS page ([Web]) or the ASHP REMS Resource Center ([Web]). (Also see Restricted Distribution Program under Dosage and Administration.)

Side effects include:

Nasopharyngitis, upper respiratory tract infection, rash, eczema, influenza, dermatitis, oropharyngeal pain, bronchitis, pharyngitis, depression, lymphadenopathy, increased ALT concentrations.

For Healthcare Professionals

Applies to daclizumab: intravenous solution, subcutaneous solution

Cardiovascular

Common (1% to 10%): Lymphadenopathy, lymphadenitis

Dermatologic

Very common (10% or more): Rash (i.e., erythematous rash, exfoliative rash, macular rash, maculopapular rash, papular rash, pruritic rash, rash, vesicular rash) (11%)

Common (1% to 10%): Dermatitis (i.e., allergic dermatitis, atopic dermatitis, bullous dermatitis, dermatitis, exfoliative dermatitis, seborrheic dermatitis, eczema, allergic dermatitis), folliculitis, acne, psoriasis, erythema, pruritus, dry skin

Uncommon (0.1% to 1%): Toxic skin eruption, eczema nummular

Gastrointestinal

Common (1% to 10%): Tonsillitis, diarrhea

Frequency not reported: Colitis

Hematologic

Common (1% to 10%): Anemia, lymphocyte count decreased

Hypersensitivity

Frequency not reported: Anaphylaxis

Respiratory

Very common (10% or more): Nasopharyngitis (25%), upper respiratory tract infection (17%)

Common (1% to 10%): Bronchitis, pneumonia, laryngitis, rhinitis

Psychiatric

Common (1% to 10%): Depression

Other

Common (1% to 10%): Oropharyngeal pain, pyrexia

Hepatic

Common (1% to 10%): ALT increased, AST increased, liver function test abnormal, hepatic enzymes increased

Immunologic

Common (1% to 10%): Influenza, viral infection

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Zinbryta